CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 21 - 30 of 888
Study Number Lead Group Study Title CIRB Study Status
ACOSOG-Z4099 ACSOG A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)<br><br> Adult CIRB - Late Phase Emphasis Completed
E2906 ECOG Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy; Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years) Adult CIRB - Late Phase Emphasis Available to Open
A041202 Alliance A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL) Adult CIRB - Late Phase Emphasis Available to Open
EA4181 ECOG-ACRIN A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 years old with Untreated Mantle Cell Lymphoma Adult CIRB - Late Phase Emphasis Available to Open
S1203 SWOG A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML) Adult CIRB - Late Phase Emphasis Available to Open
A031704 Alliance PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE] Adult CIRB - Late Phase Emphasis Available to Open
RTOG-P-0011 RTOG Phase III Randomized Study of Adjuvant Therapy For High Risk PT2-3N0 Prostate Cancer Adult CIRB - Late Phase Emphasis Completed
S1914 SWOG A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC Adult CIRB - Late Phase Emphasis Available to Open
EA5181 ECOG-ACRIN Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC Adult CIRB - Late Phase Emphasis Available to Open
CALGB-90202 CALGB A Randomized Double-Blind; Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone Adult CIRB - Late Phase Emphasis Completed
Displaying 21 - 30 of 888